Cassava Sciences, Inc. - Common Stock (NQ:SAVA)

2.380 UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences, Inc. - Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

38 39 Next >

Snowflake (SNOW) Stock Is Sliding Despite AI Hopes ↗

August 24, 2023

Snowflake (SNOW) stock is on the move Thursday following the release of the company's second-quarter earnings report for fiscal 2024.

Via InvestorPlace

Topics Artificial Intelligence

Is Splunk (SPLK) Stock the Next AI Giant? ↗

August 24, 2023

Splunk (SPLK) stock climbed higher on Thursday as investors weighed the company's value in the AI market following its earnings report.

Via InvestorPlace

Topics Artificial Intelligence

Insider Richard Barry Just Doubled Down on Cassava (SAVA) Stock ↗

August 24, 2023

Cassava had $168.4 million of cash at the end of June after losing $28.7 million during the second quarter of 2023. SAVA stock is up 5%

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 14, 2023

Via Benzinga

Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates

August 03, 2023

From Cassava Sciences, Inc.

Via GlobeNewswire

Why Cassava Sciences Stock Is Trading Down Today ↗

July 05, 2023

Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading lower Wednesday.

Via Benzinga

Why Shares of Cassava Sciences Are Dropping Wednesday ↗

July 05, 2023

The company announced phase 3 trial results for its lead Alzheimer's therapy.

Via The Motley Fool

Stocks That Hit 52-Week Lows On Friday ↗

August 11, 2023

During the Friday's sesion, 157 stocks hit new 52-week lows.

Via Benzinga

Why These 3 Stocks Are the Worst Ways to Play Biotech Right Now ↗

July 13, 2023

These three worst biotech stocks are not investable even if you're bullish on the sector overall. There are better options.

Via InvestorPlace

7 Biotech Stocks to Sell in July ↗

July 13, 2023

Running the gamut from large to small, and from commercial stage to clinical stage, these are seven top biotech stocks to sell in July.

Via InvestorPlace

Why Shares of Cassava Sciences Jumped This Week ↗

May 12, 2023

Cassava Sciences finished dosing in one of its phase 3 trials for its Alzheimer's therapy Simufilam.

Via The Motley Fool

Why Is Cassava Sciences (SAVA) Stock Up 15% Today? ↗

May 09, 2023

Today, shareholders in Cassava Sciences and SAVA stock are cheering some positive research data for its key drug candidate.

Via InvestorPlace

FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline ↗

July 07, 2023

The FDA fully approved Biogen Inc.’s (NASDAQ: BIIB) Alzheimer’s treatment Leqembi on Thursday, becoming the first Alzheimer’s antibody treatment to reach full approval.

Via Benzinga

Stock Market Round-Up: Rivian Rides High, Meta Platforms Makes Moves, And Tesla Ticks Up ↗

July 05, 2023

Via Benzinga

Cassava Sciences (SAVA) Stock Drops Despite Positive Trial Results ↗

July 05, 2023

Cassava Sciences (SAVA) stock is down 11% on underwhelming results from its Phase 3 clinical trials for its Alzheimer's treatment.

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

July 05, 2023

Via Benzinga

Dow, S&P 500 Move Lower On Renewed Fed Fatigue ↗

July 05, 2023

Stocks are moving lower ahead of the Federal Reserve's June meeting minutes, which are due out this afternoon.

Via Talk Markets

Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

July 05, 2023

Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares surged 87% to $11.78 after the company said the initial data from Phase 2 trial of Ixempra shows potential for improved clinical benefit in...

Via Benzinga

Promising Alzheimer's Treatment: Cassava Sciences' Simufilam Slows Cognitive Decline by 38% in Clinical Study ↗

July 05, 2023

Cassava Sciences Inc (NASDAQ: SAVA) announced topline clinical results from its Cognition Maintenance Study (CMS), a small proof-of-concept study designed to demonstrate the effects of simufilam versus...

Via Benzinga

Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease

July 05, 2023

From Cassava Sciences, Inc.

Via GlobeNewswire

New Research Shows Simufilam Suppresses Overactive mTOR

June 27, 2023

From Cassava Sciences, Inc.

Via GlobeNewswire

New Publication Highlights Basic Science Supporting Simufilam

June 12, 2023

From Cassava Sciences, Inc.

Via GlobeNewswire

Cassava Sciences to Present at the Jefferies Global Healthcare Conference

June 01, 2023

From Cassava Sciences, Inc.

Via GlobeNewswire

3 Biotech Stocks to Avoid Like the Plague ↗

May 23, 2023

Investors are looking for bargains in the biotech sector. But these three biotech stocks should be avoided at all costs.

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

May 22, 2023

Via Benzinga

Hero or Zero? 7 High-Risk Stocks to Make You Rich… Or Broke. ↗

May 21, 2023

These seven high-risk stocks could ultimately rocket to the moon, or fall to the depths of the stock market graveyard.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 18, 2023

Via Benzinga

Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer’s Disease

May 11, 2023

From Cassava Sciences, Inc.

Via GlobeNewswire

Top 5 Health Care Stocks That May Collapse In Q2 ↗

May 10, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A

May 08, 2023

From Cassava Sciences, Inc.

Via GlobeNewswire

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.